Short answer
Fulgent Genetics, Inc. (FLGT) filed an 8-K current report with the SEC on May 1, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Fiscal quarter ended March 31, 2026 results announced by Fulgent Genetics.
Fulgent Genetics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Fiscal quarter ended March 31, 2026 results announced by Fulgent Genetics
- Press release furnished as Exhibit 99.1, containing the detailed financial results
Item 7.01 · Regulation FD Disclosure
- Updated investor presentation released May 1, 2026, providing refreshed business and strategy information
- Presentation available through Fulgent Genetics’ investor-relations website and furnished as Exhibit 99.2
- Disclosure furnished under Regulation FD, limiting Section 18 liability and automatic incorporation into registration statements
Item EX-99.1 · Exhibit EX-99.1
- Q1 2026 revenue $71M, down 3% year over year, signaling modest near-term pressure in laboratory services
- Bako and StrataDx acquisition closed March 17, 2026 for $56.3M, expanding pathology capacity and nearly doubling pathology sales headcount
- LTM operating cash flow $(90)M, with $106M federal tax refund delayed and creating near-term liquidity sensitivity
- 2026 cash, cash equivalents, and investments guidance approximately $636M, assuming $106M tax refund receipt and $26M therapeutic-development spending
- FID-007 Phase 2 preliminary ORR 51% and DCR 74% across 35 efficacy-evaluable patients, supporting continued oncology development but remaining non-final data
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Fulgent Genetics, Inc. 8-K filings
Get the next FLGT 8-K as it lands
Follow FLGT for push alerts, or ask the research agent what this filing means.